Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB103 in Advanced Solid Tumors
NCT07459998Phase 2Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Apr 2026
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SKB103 in solid tumor, sponsored by Kelun-Biotech. Primary endpoints: Dose-limiting toxicity up to 21 days and Objective Response Rate. Started Apr 2026; status: recruiting.
02
Drugs
SKB103
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07459998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459998.